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Abstract
Primary myelofibrosis (PMF) is a Philadelphia-negative (Ph−) myeloproliferative disorder,
showing abnormal CD34+ progenitor cell trafficking, splenomegaly, marrow fibrosis leading
to extensive extramedullary haematopoiesis, and abnormal neoangiogenesis in either the
bonemarrow or the spleen. Monocytes expressing the angiopoietin-2 receptor (Tie2) have
been shown to support abnormal angiogenic processes in solid tumors through a paracrine
action that takes place in proximity to the vessels. In this study we investigated the frequency
of Tie2 expressing monocytes in the spleen tissue samples of patients with PMF, and healthy
subjects (CTRLs), and evaluated their possible role in favouring spleen angiogenesis. We
show by confocal microscopy that in the spleen tissue of patients with PMF, but not of
CTRLs, the most of the CD14+ cells are Tie2+ and are close to vessels; by flow cytometry, we
found that Tie2 expressing monocytes were Tie2+CD14lowCD16brightCDL62−CCR2− (TEMs)
and their frequency was higher (p = 0.008) in spleen tissue-derived mononuclear cells
(MNCs) of patients with PMF than in spleen tissue-derived MNCs from CTRLs undergoing
splenectomy for abdominal trauma. By in vitro angiogenesis assay we evidenced that condi-
tioned medium of immunomagnetically selected spleen tissue derived CD14+ cells of
patients with PMF induced a denser tube like net than that of CTRLs; in addition, CD14+Tie2+
cells sorted from spleen tissue derived single cell suspension of patients with PMF show a
higher expression of genes involved in angiogenesis than that found in CTRLs. Our results
document the enrichment of Tie2+ monocytes expressing angiogenic genes in the spleen of
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patients with PMF, suggesting a role for these cells in starting/maintaining the pathological
angiogenesis in this organ.
Introduction
Primary myelofibrosis (PMF) is a Philadelphia-negative (Ph−) myeloproliferative disorder of
unknown aetiology, characterized by the presence of acquired mutations of either JAK2, or
MPL, or CALR genes in the myeloid cells of 90% of the patients [1], abnormal CD34+ progeni-
tor cell trafficking [2], splenomegaly, and marrow fibrosis leading to extensive extramedullary
haematopoiesis [3].
Neoangiogenesis has been documented in the bone marrow (BM) of patients with PMF,
and microvessel density has been reported to be higher than in other chronic myeloprolifera-
tive disorders [4]. Similarly, it has been shown an up to three-times increased capillary vascular
density in the spleen of patients with PMF and splenomegaly, suggesting a significant contribu-
tion of neoangiogenesis to the spleen volume expansion [5]. This hypothesis is strengthened by
previous observations of reduction of spleen volume with anti-angiogenic therapy [6, 7], and
by the observation that responders to the treatment were patients with a documented increase
in BM angiogenesis [8]. In keeping with this notion we documented an increased number of
circulating putative endothelial progenitor cells (EPCs) in the peripheral blood (PB) and spleen
of patients with PMF [9], and an increased frequency of endothelial colony forming cells
(ECFCs) in the PB of patients with PMF and with myeloproliferative disorders with high risk
of splanchnic vein thrombosis [10].
CD14lowCD16bright non classical monocytes expressing the angiopoietin-2 receptor (Tie2)
have been shown to support abnormal angiogenic processes in solid tumors through a para-
crine action that takes place in close proximity to the vessels [11, 12, 13]. More recently,
CD14brightCD16low intermediate monocytes have also been reported to selectively up-regu-
late the expression of genes codifying for Tie2, the vascular endothelial growth factor
(VEGF) receptor 2, and endoglin, and have been defined as angiogenic monocytes [14]. In
this line of evidence, in patients with PMF we reported an increased frequency of PB
CD14brightCD16lowTie2+ angiogenic monocytes that was correlated with the severity of the
disease [15].
In this study we have investigated the frequency of CD14lowCD16bright non classical mono-
cytes expressing Tie2 in spleen tissue samples of patients with PMF and healthy subjects under-
going splenectomy for clinical reasons or abdominal trauma, respectively. To the best of our
knowledge, no data are available on the presence of angiogenic monocytes in the spleen of
patients with PMF, and their possible role in fuelling the well documented abnormal angiogen-
esis that characterizes this organ.
Materials and Methods
Patients
Sixteen patients with PMF in whom splenectomy was indicated because of refractory and
symptomatic splenomegaly, entered the study (Table 1). The diagnosis of PMF was established
according to World Health Organization Criteria [16]. At time of sampling patients were
receiving androgens (n = 3), oncocarbide (n = 8), steroids (n = 2; one until 6 months before
splenectomy), or red cell transfusions (n = 1); two patients were out of therapy (withdraw ruxo-
litinib 6 and 3 months before splenectomy, respectively). A risk class was assigned to all the
Tie2 Expressing Monocytes in PMF
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patients included in the study according to the DIPSS score [17]. Spleen tissue samples were
obtained from 6 CTRLs who underwent splenectomy for traumatic lesions (median age 50,
range 32–65).
PB of 73 consecutive patients with PMF, collected from 14 Italian Centers participating to
the Italian Registry of MF, were studied (S1 Table). Patients (95%) were studied before receiv-
ing treatment; the spleen size and index [18], prognostic score and severity score [19] were cal-
culated. PB samples from 13 healthy individuals (CTRLs) 7 males and 6 females (median age
53 years, 23–68) were studied.
The study was approved by the IRCCS Policlinico S. Matteo Foundation’s institutional
review board (approval number 2011–0004143). All clinical investigations have been con-
ducted according to the principles expressed in the Declaration of Helsinki. Written informed
consent was obtained from each patient included in the study.
Spleen tissue
Spleen tissue specimens from 3 patients with PMF and 3 CTRLs were embedded in OCT com-
pound (VWR, Leuven, Belgium), snap-frozen in liquid nitrogen and cut into 3-μm-thick sec-
tions. Alternatively, tissue specimens were reduced to a single cell suspension by Gentle MACS
Dissociator (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and mononuclear cells
(MNCs) obtained by density gradient centrifugation. CD3+ and CD14+ cells were purified
from spleen tissue-derived MNCs by immunomagnetic selection (MACS, Miltenyi Biotec).
Megakaryocytes (MKs) were obtained in vitro from CD34+ spleen tissue-derived cells and cul-
tured as previously reported [20].
Spleen tissue derived MNCs, CD14+ monocytes, or CD3+ cells and MKs were cultured in
24-well plate (2x106/well) in RPMI 1640 medium supplemented with 10% FCS (both Euro-
clone SpA, Milan, Italy). After 3 days at 37°C, 5% CO2, the supernatants were collected, centri-
fuged at 1200 rpm for 10 min and the conditioned medium (CM) stored at -80°C.
Flow cytometric analysis of Tie2-expressing monocytes
Spleen tissue-derived or PBMNCs were stained with PeCy7-anti-CD14, FITC-anti-CD16,
APC-anti-Tie2, PE-anti-CD62L and PerCP-anti-CCR2 (R&D Systems, Minneapolis, MN or
Table 1. Characteristics of patients with primary myelofibrosis (PMF) whose spleen was available for
this study.
n
Age, years, median (range) 16 65 (51–78)
Males, number (%) (54.5%)
Spleen size, (cm2), median (range) 8 467 (300–744)
Time from diagnosis to splenectomy, months, median (range) 16 67 (13–202)
CD34+ cells in peripheral blood/microliter, median (range) 16 68 (19–429)
Dupriez risk score*, number (%)
0 4 (25)
1 7 (44)
2 5 (31)
* A DIPSS score of 0 (low risk) was assigned for haemoglobin level greater than 10 g/dl and a blood cell
count between 4x109/l and 30x109/l, score of 1 (intermediate risk) for either a haemoglobin level less than
10g/dl or a white blood cell count greater than 30x109/l or less than 4x109/l, and a score of 2 (high risk) if
both the haemoglobin level and white blood cell count were in the aberrant ranges.
doi:10.1371/journal.pone.0156990.t001
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eBioscience, San Diego, CA). According to Venneri et al. [13] angiogenic monocytes, acquired by
a flow cytometer (Navios™; Beckman Coulter, Inc, Brea, CA) and analyzed by Kaluza1 flow anal-
ysis software (Beckman Coulter), were identified as Tie2+ CD14lowCD16brightCD62L−CCR2−
cells. The appropriate isotype controls were used to set the markers for positive/negative cells (see
Fig 1 and S1 Fig). We evaluated the percentage of total CD14+ cells in PB or spleen tissue-derived
MNCs of patients with PMF and CTRLs; the percentage of Tie2+ cells was investigated on
MNCs, CD14+, CD14lowCD16bright, and CD14lowCD16brightCD62L−CCR2− cells. Data were
shown as median (range).
Immunofluorescence and confocal microscopy
Spleen tissue samples snap-frozen in liquid nitrogen were cut into 3-μm-thick sections. Follow-
ing fixation, permeabilization, and blocking, sections were incubated with rabbit anti-human
Fig 1. Cytofluorimetric analysis of spleen tissue derived TEMs.CD14lowCD16bright non classical monocytes from a patient with PMF
were gated (panel A); CD14lowCD16bright not expressing the CD62L and CCR2 antigens on the membrane (panel B) were than evaluated
for the expression of Tie2 (panel C). Panels D, E, F for one representative healthy subject (CTRL).
doi:10.1371/journal.pone.0156990.g001
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Tie2 (polyclonal) and mouse anti-human CD14 (monoclonal) antibodies. Alexa Fluor 488
anti-rabbit, and Alexa Fluor 555 anti-mouse (Invitrogen, Carlsbad, CA) were used as secondary
antibodies. Slides were counterstained with DAPI (Sigma Aldrich, St. Luis, MO). The images,
obtained by confocal laser scanning microscopy (Leica TCS SP2, 63x objective), were processed
by Photoshop software (Adobe Systems Incorporated, Mountain View, CA, USA).
The frequency of CD14+ and CD14+Tie2+ cells in the spleen tissue sections of patients with
PMF and CTRLs were calculated by ImageJ software (National Institute of Health, USA, http://
rsbweb.nih.gov/ij/.) using the formula: number of CD14+Tie2+ x 1000/total DAPI+ cells in
each section.
In vitro angiogenesis assay
Endothelial colony forming cells (ECFCs) were obtained from PB of healthy subjects, as previ-
ously described [10]. Cells from early passage (P1–P2) ECFCs were isolated by trypsinization
and resuspended in EBM2 medium (Lonza, Basel CH) in the presence of 10% FCS. Two x 104
ECFC-derived cells per well were plated onto 96 well plates coated with Cultrex1 basement
membrane extract (Trevigen1, Gaithersburg, MD, USA), in the presence of 20% of CM from
spleen derived MNCs, immunomagnatically selected CD3+ or CD14+ cells, or MKs. Plates
were then incubated at 37°C, 5% CO2 and capillary-like network formation was assessed start-
ing from 4 hours later and up to 24 hours. At least 2 different sets of cultures were performed
for each experimental point. Quantitative evaluation of the total length of tube-like structures
was assessed by measuring the ratio of the tube length in the assays performed with MNC,
MNC subset, or MK CM (mm)/surface of the field (mm2) by ImageJ software (National Insti-
tute of Health, USA, http://rsbweb.nih.gov/ij/.).
Sorting of Tie2+ monocytes
CD14+ cells of 2 patients with PMF were selected from spleen tissue-derived MNCs by
immuno-magnetic selection (MACS, Miltenyi Biotec). From pooled CD14+ cells, CD14+Tie2+
and CD14+Tie2− cells were then sorted by FACS-sorting (BD FACSAria™ II, BD Biosciences)
with purity greater than 95% for each subset (S2 Fig).
RNA isolation and whole-transcriptome amplification (WTA)
RNA from CD14+, CD14+ Tie2+, and CD14+ Tie2− sorted cells was purified by RNeasy Plus
Micro kit (Qiagen, Hilden, Germany) and used for amplification (50 ng for the CD14+ cells
and the total RNA sample for the CD14+ Tie2+ and CD14+ Tie2− cells). Library preparation
was performed following the distributor’s (Sigma-Aldrich, St Louis, MO, USA) recommenda-
tions for the Complete Whole Transcriptome Amplification Kit (S1 Appendix).
Gene expression analysis
Predesigned primers (Sigma-Aldrich) were used for EvaGreen assays (S2 Table). Quantifica-
tion of transcripts was carried out in a 15 μl reaction mix containing 1X SsoFast EvaGreen
Supermix (Bio-Rad, Hercules, CA, USA), 400 nM of each primer and 10 ng of purified WTA-
cDNAs. The PCR data were collected using the CFX96 Real-Time System (Bio-Rad). Each
sample was tested in duplicate. Calculation of normalized relative expression levels (fold
change) and error propagation (standard error) was done using the Qbase Plus software ver-
sion 3 (Biogazelle, Gent, Belgium). Normalization was performed using the two most stably
expressed reference genes which were selected using the geNorm algorithm, among the
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following candidates: YWHAZ, GAPDH, HPRT1, UBC, B2M. A validation of results was per-
formed (S1 Appendix).
Statistical analysis
Groups were compared by means of Mann-Whitney U-test for unpaired samples, one-way-
repeated-measures-ANOVA and Bonferroni’s test as a post hoc test, or Wilcoxon for paired
samples. All computations were performed with STATISTICA software (StatSoft, Inc.Tulsa,
OK).
Results
Patient characteristics
The clinical characteristics of patients with PMF enrolled at time of splenectomy (n = 16) of
whom we obtained spleen tissue samples are shown in Table 1 (see Material and Methods
section).
Perivascular CD14+Tie2+ cells in the spleen tissue samples of patients
with PMF
We performed immunofluorescence studies on snap frozen spleen tissue sections of patients
with PMF (n = 3) and CTRLs (n = 3). Our staining protocol did not include the anti-CD16
antibody since it is well known that only CD16+ monocytes can express the Tie2 antigen [13].
We found that in the spleen tissue samples from patients with PMF the most of the CD14+
cells co-expressed Tie2 on the membrane and some of them were close to vessels (Fig 2, upper
panels for one representative patient). In the 3 spleen tissue sections from patients with PMF
the median frequency of CD14+ cells was 44/1000 cells (range 41–48), while the median fre-
quency of CD14+Tie2+ cells was 20/1000 cells (range 14–25). In spleen tissue sections from
CTRLs (n = 3), the median frequency of CD14+ cells was comparable (median 30/1000, range
9–52) to that found in tissue sections from patients with PMF; however, in none of the sections
were observed monocytes co-expressing the Tie2 antigen (Fig 2, lower panels for one represen-
tative CTRL).
Evaluation of Tie2+ monocytes in the spleen tissue-derived MNCs of
patients with PMF and CTRLs
To further investigate the phenotype of the CD14+Tie2+ cells evidenced by confocal micros-
copy, by flow cytometry we evaluated the total CD14+ or Tie2+ cells on spleen tissue derived
MNCs of patients with PMF (n = 16) and healthy subjects (CTRLs) (n = 6). In addition, we
measured the percentage of Tie2+ cells on CD14+, CD14lowCD16bright non classical monocytes,
and CD14lowCD16brightCD62L−CCR2− cells. As shown in Table 2, while the percentage of
CD14+ cells or Tie2+ cells among the MNCs was comparable between patients and CTRLs, the
percentage of CD14+ cells expressing Tie2 was higher (p = 0.027) in patients with PMF than in
CTRLs. Similarly, the frequency of CD14lowCD16bright monocytes expressing Tie2 was signifi-
cantly higher (p = 0.028) in the spleen tissue-derived MNCs of patients with PMF than in
CTRLs. We focalized on this last cell subset assessing the lack of membrane antigens such as
CD62L (a member of the selectin family of adhesion molecules that facilitate rolling of inflam-
matory leukocytes along the vascular endothelium) and CCR2 (the monocyte-chemoattractant
protein-1 receptor, a chemokine involved in the recruitment of inflammatory monocytes),
defining monocytes recruited through non inflammatory pathways (i.e. angiogenic pathways).
The percentage of CD14lowCD16brightCD62L−CCR2− cells expressing Tie2 (TEMs) [13] was
Tie2 Expressing Monocytes in PMF
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significantly higher (p = 0.008) in the spleen tissue-derived MNCs of patients with PMF than
of CTRLs (Table 2, Fig 1 and S1 Fig for the cytofluorimetric analysis of one representative
patient and CTRL).
We evaluated TEMs in paired samples of PB MNCs (blood sample was obtained just before
the splenectomy) and spleen tissue-derived MNCs of patients with PMF (n = 6). The percent-
age of TEMs was significantly higher (p = 0.040) in the spleen compartment than in the PB; in
Table 2. Evaluation of CD14+ cell and cell subsets in spleen derived MNCs of patients with primary myelofibrosis (PMF) and of healthy subjects
(CTRLs). Data are shown as median (range).
PMF CTRLs
Evaluated as (n = 16) (n = 6) p vs CTRLs
CD14+ % MNCs 7.3(0.7–25) 7.0(2.0–19) 0.6
Tie2+ % MNCs 6.0(1.6–41.3) 2.3(0.4–24) 0.13
Tie2+ %CD14+ 27(6.0–70) 6.4(1.8–16) 0.027
Tie2+ % CD14lowCD16bright 8.0(2.3–50) 3.0(0.2–5.4) 0.028
Tie2+ % CD14lowCD16brightCD62L−CCR2−(TEMs) 9.2(0.8–47.5) 1.6(0–6.8) 0.008
doi:10.1371/journal.pone.0156990.t002
Fig 2. Confocal microscopy images of spleen tissue samples stained with anti-CD14 and anti-Tie2. Spleen tissue samples were
immunostained for the indicated markers and a small capillary from each stained specimen was chosen for display. A) Arrow heads indicate
cells expressing both CD14 in red (i) and Tie2 in green (ii) in the perivascular area of spleen tissue sample from 1 representative patient with
primary myelofibrosis (PMF). The yellow colour indicates colocalization of CD14 and Tie2 (iii). B) Thin arrows indicate CD14+ cells (iv) not
expressing Tie2 (v, vi) in spleen tissue sample from 1 representative CTRL. DAPI (blue) was used as the nuclear marker and the images
were incorporated in the merge panels (iii, vi). Images were obtained at 63x magnification.
doi:10.1371/journal.pone.0156990.g002
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addition, the PB TEM frequency was significantly lower (p = 0.002) in patients with PMF than
in CTRLs (n = 13) who volunteered a PB sample (Table 3).
Spleen recruitment of TEMs in patients with PMF
To evaluate the hypothesis of a recruitment of TEMs from the PB to the spleen compartment
we analysed PB TEMs in 73 consecutive patients with PMF; we divided these patients accord-
ing with their spleen size at time of sampling. Patients with a spleen size within the range of
CTRLs (100 cm2) had a frequency of PB TEMs significantly higher (p = 0.000003) than that
found in patients with a spleen size greater than 100 cm2 (range 108–782 cm2), and comparable
to that of CTRLs (Table 4).
To further investigate this aspect, we evaluated the frequency of PB TEMs of patients with
PMF (n = 9) assessed after splenectomy, with a median time from the surgical intervention of
30 months (range 2–96). In these patients the percentage of circulating CD14+ cells (12, range
5–27) was comparable to that of CTRLs; the percentage of PB TEMs (27.5, range 2–57) was
comparable to that of CTRLs and significantly higher (p = 0.02) than that of patients with PMF
tested before splenectomy (Table 3).
Increased angiogenic potential of spleen tissue derived MNC
conditioned medium (CM) from patients with PMF
We cultured spleen derived MNCs in RPMI 1640 medium supplemented with 10% FCS for 3
days at 37°C (see Material and Methods section); the CM samples of 7 patients with PMF and
6 CTRLs were added to ECFC-derived ECs from a healthy subject to evaluate their in vitro
capacity to induce tube-like structure formation. We observed that the net of tube-like struc-
ture was denser in presence of the spleen MNC CM of patients with PMF than in presence of
the spleen MNC CM of CTRLs (Fig 3, panel A for 2 representative patients and 1 CTRL). The
formation of tube-like structures with unconditioned medium was performed and resulted
negligible (not shown). The total length of tube-like structures, assessed by measuring the ratio
of the tube length in the assays performed with spleen MNC CM (mm)/surface of the field
(mm2), was significantly higher (p = 0.02) in presence of the CM from patients with PMF with
respect to that obtained with CM from CTRLs (Fig 3, panel C, left side).
Table 3. Evaluation of TEMs in paired samples of peripheral blood (PB) and spleen tissue derived
MNCs of patients with primarymyelofibrosis (PMF) and in the PB of healthy not splenectomised sub-
jects (CTRLs). TEMs are shown as median (range).
n PB TEMs Spleen TEMs p
PMF 6 4.8(0–11) 27 (2.6–55.6) 0.04
CTRLs 13 20.2 (10–29) NA NA
p PMF vs CTRLs 0.002
doi:10.1371/journal.pone.0156990.t003
Table 4. Evaluation of TEMs in the peripheral blood (PB) of patients with primary myelofibrosis (PMF)
divided according with the spleen size. Data are shown as median (range).
Patients with PMF n PB TEMs pvs CTRLs
Spleen size  100 cm2 35 24.1 (2.2–34.2)* 0.07
Spleen size >100 cm2 (range 108–782 cm2) 38 8.1 (0–38) 0.002
* p = 0.000003 patients with spleen size 100 cm2 vs patients with spleen size >100 cm2
doi:10.1371/journal.pone.0156990.t004
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To better characterize, among the spleen derived MNCs, those producing angiogenic fac-
tors, we separately cultured MKs (see Material and Methods section), and immuno-magneti-
cally selected CD3+ or CD14+ cells from patients with PMF (n = 3) and CTRLs (n = 2). When
CMs from these cultures were added to ECFC-derived ECs from a healthy subject, we observed
that the total length of tube-like structures was increased in presence of the CM from CD14+
cells of 2 out of 3 patients with PMF with respect to that obtained with CMs from CD14+ cells
of CTRLs (Fig 3, panel B for a representative patient and a CTRL). The formation of tube-like
structures with CMs from CD3+ cells or MKs was negligible (not shown). The quantitative
evaluation of the tube-like structures obtained with the CD14+ CM of either patients with PMF
and CTRLs is shown (Fig 3, panel C, right side).
Gene signature of spleen tissue derived CD14+Tie2+ cells
In order to investigate the pro-angiogenic activity of monocytes, we immuno-magnetically
purified total CD14+ cells from 2 patients with PMF; from pooled CD14+ cells CD14+Tie2+,
and CD14+Tie2− cells were sorted (S2 Fig). Purification of CD14+Tie2+ cells was technically
challenging because of their low frequency; we therefore used a quantitative PCR approach
that allows to analyse gene expression from small amounts of mRNA (see Material and Method
Fig 3. In vitro tubulogenesis induced by spleen MNC or selected CD14+ cell CM. Digital images of endothelial tubes
obtained by bright-field light microscopy 24 hours after plating Endothelial Colony Forming Cells from a healthy donor on
Matrigel-coated wells in presence of CM of spleen tissue derived MNCs from two patients with primary myelofibrosis
(PMF) and one representative CTRL (panel A), or CM of spleen tissue derived selected CD14+ cells from one
representative patient with PMF and one CTRL (panel B). Cultures were examined under an inverted microscope
(Labovert, Leitz, Germany) in bright field, at 2.5X magnification using a PL (Leitz Wetzlar, Germany) objective; quantitative
evaluation of the tube-like structures, expressed as ratio of the total length of tubular structures per field (mm)/surface of
the field (mm2) (ImageJ software by National Institutes of Health, USA, http://rsbweb.nih.gov/ij/.), of all the patients with
PMF and CTRLs tested is shown (panel C).
doi:10.1371/journal.pone.0156990.g003
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section). To study the nature of CD14+Tie2+ cells, we measured the expression of genes previ-
ously implicated in angiogenesis, tissue remodelling, immune response, cell adhesion, chemo-
taxis, and haematopoiesis (S2 Table). A list of the genes differentially expressed in CD14+Tie2+
with respect to CD14+Tie2− cells and total CD14+ cells is shown (Table 5). Among them there
were genes codifying monocyte/macrophage-derived cytokines (IL1β), and matrix related pro-
teins such as Heparanase (HPSE) that have been widely demonstrated to increase microvessel
density and reduce survival of cancer patients. In addition, we evidenced a high mRNA expres-
sion of genes that promote angiogenesis and cell survival, thymidine phosphorylase/endothelial
cell growth factor 1 (TYMP/Ecgf1) and Catenin beta1 (CTNNB1), important mediators of epi-
thelial cell-cell adhesion, further supporting the pro-angiogenic role of these cells. Similarly,
the higher expression of the gene codifying for CXCR4 on monocytes has been described to
characterize populations of monocytes with angiogenic and reparative potential.
Discussion
In this study we assessed the frequency of TEMs in the spleen of patients with PMF, their possi-
ble origin, and their role in fuelling the spleen abnormal angiogenesis.
In fact, we have previously shown by immuno-histochemistry that, although the frequency
of circulating EPCs was increased, no strict correlation was ever found between the degree of
spleen angiogenesis and these cells evaluated by either cytofluorimetric analysis or in vitro cul-
ture of ECFCs [9 and personal observations].
In the last years, a number of studies performed in animal models have been published
attributing to Tie2 expressing monocytes a role in favouring angiogenesis through a paracrine
action [11, 21, 22]. The results in humans are more discordant. Matsubara et al described
CD14lowCD16brightTie2+ angiogenic monocytes both in the PB and tumor site of patients with
hepatocellular carcinoma; these cells were increased and correlated with the therapeutic
response, the degree of tumoral vascularisation, and were observed in close proximity to vessels
in tumor tissue [23]. At variance, Goede et al studied patients with colorectal cancer and found
no correlation among the frequency of CD14+Tie2+ cells in both PB and tumor tissue, the
tumor stage or the angiogenic processes [24]. These discrepancies may be related to the differ-
ent kind of tumors studied and the different phenotypic analysis of these cells; however, the
Table 5. Genes differentially expressed in CD14+Tie2+ and CD14+Tie2− or total CD14+ cells (CD14+ tot).
Genes Fold change (SEM)
CD14+Tie2+vs CD14+Tie2− CD14+Tie2+vs CD14+ tot ΔCq Tie2+ ΔCq Tie2− ΔCq CD14+ tot
CXCR4 11.7 (0.6) 0.6 (0.1) 2.7 5.4 1.2
CTNNB1 6.9 (0.6) 3.0 (0.3) 4.1 6.1 4.8
TIMP1 3.1 (0.2) 1.4 (0.1) 6.2 7.0 5.9
SPI1 4.1 (0.2) 0.9 (0.1) 8.4 9.6 7.3
TYMP n.a. 36.5 (1.3) 3.1 n.a. 7.5
HPSE 18.6 (1.8) 2.1 (0.2) 7.3 10.7 7.5
IL1B 5.3 (0.5) 1.2 (0.1) 9.2 10.8 8.5
The expression level of each gene in Tie2+ is indicated as fold-change versus Tie2− or CD14+ tot. The values were calculated using the two most stable
reference genes (UBC and GAPDH).
ΔCq is used to represent the expression level of each gene compared to the others in each cell type (approximately the lower the ΔCq the higher the
expression level). The ΔCq of each gene was calculated using UBC as reference gene.
Each data point represents the average of 2 technical replicates of the same sample.
doi:10.1371/journal.pone.0156990.t005
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contribution of Tie2+ monocytes belonging to the non classical/intermediate subset to the
angiogenic processes has been recently confirmed in a study that describes their role in improv-
ing the revascularization of the ischemic limb in both animal models and humans [21].
In a previous study our group documented the significant increase of the angiogenic subset
of CD14brightCD16low intermediate monocytes expressing Tie2+ in the PB of patients with
PMF, and the possible use of this parameter as a biomarker [15].
In this study, by confocal microscopy, we showed that CD14+ cells co-expressing Tie2 accu-
mulate in spleen tissue of patients with PMF, some in close proximity to vessels, without show-
ing direct connections, while no monocyte expressing Tie2 is present in spleen tissue samples
from CTRLs. These novel findings were all in agreement with data found in human and murine
solid tumors, where monocytes were described to contribute to the tumor angiogenesis [11,
13].
Interestingly, when we analysed the spleen tissue derived angiogenic monocytes from
patients with PMF by flow cytometry, the highly represented phenotype was Tie2+-
CD14lowCD16bright CD62L−CCR2− (TEMs) at variance with our previous finding in the PB
compartment, where the CD14brightCD16low intermediate monocytes expressing Tie2 were
significantly increased [15]. These data suggest that angiogenic monocytes migrating toward
tissues are non classical monocytes (i.e. macrophages), while circulating angiogenic mono-
cytes belong to an earlier maturation step (intermediate monocytes) [14].
It has recently been described a treatment-related increase of CD14brightCD16low intermedi-
ate monocytes due to glucorticoids [25]; however, since only 1/16 patients with PMF was
receiving steroids at time of splenectomy, while the most was receiving oncocarbide that induce
mainly myelosuppression [26], our data indicate that the increased frequency of TEMs in the
spleen of patients with PMF can be considered disease-related.
Regarding the origin of TEMs found in the spleen tissue, it is important to point out that the
spleen of patients with PMF is one of the organs where extra-medullary haematopoiesis is
active after BM fibrosis takes place. In addition, we found that the frequency of TEMs is higher
in spleens with a size greater than 100 cm2 with respect to those with a size minor than 100
cm2; therefore, the generation of the monocyte/macrophage lineage, possibly including angio-
genic monocytes, within the organ could be hypothesized. However, supporting the recruit-
ment of angiogenic monocytes from the PB, their frequency in spleen tissue-derived MNCs
was higher than in paired samples of PB from patients with PMF. Moreover, in patients with
PMF who underwent splenectomy (median of 30 months from the surgery) there was a signifi-
cant increase of circulating angiogenic monocytes, with a PB frequency comparable to that of
CTRLs. Nevertheless, we cannot exclude that after the splenectomy the (re)activation of new
spots of haematopoiesis either in the BM or in other extra-medullary sites, such as liver or
lungs, could be responsible of the increased number of circulating angiogenic monocytes, while
the apparent recruitment may be related to other organs (i.e. BM).
Regarding the possible role of angiogenic monocytes in fuelling the spleen abnormal angio-
genesis, it has been described that they promote angiogenesis through a paracrine action in
close proximity to vessels. This possibility has been shown by seeding sorted CD14+Tie2+ or
CD14+Tie2− cells in presence of endothelial cells (i.e. Huvec) [22]. Two major limitations did
not allow us to perform similar experiments: the difficulty in collecting spleen tissue samples
since the splenectomy is becoming a rare, infrequent indication after the jak2 inhibitors (i.e.
Ruxolitinib) have become available in clinical practice. In addition, the low number of spleen-
derived CD14+Tie2+ cells obtained by sorting, not sufficient to assess their role in co-culture
experiments. The low efficiency of the sorting procedure could be due to the long lasting dis-
ease and the abnormal spleen size (i.e.10 times the normal one) that characterize the patients
included in this study; the number of angiogenic monocytes in the organ may not be as high as
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in the early phase of the “angiogenic switch”, therefore our results may reflect what is left of the
initial phenomenon. Nevertheless, this study documents the presence of angiogenic factors in
the CM of spleen derived MNCs of patients with PMF resulting in the formation of an abnor-
mal capillary network, denser than that measured with spleen derived MNC CM from CTRLs;
more importantly, CD14+ cells appear to be the MNC subset responsible of the production of
the angiogenic factors.
In an attempt to investigate the expression of genes involved in the angiogenic activity of
monocytes, we evaluated the gene expression profile of sorted CD14+Tie2+, CD14+Tie2− and
CD14+ cells pooled from the spleen samples of 2 patients with PMF. Although the number of
genes that we were able to validate by our technical approach is low (S2 Table) some of the
transcripts over expressed in CD14+Tie2+ cells (IL1β,HPSE, TYMP) have been previously
reported among the genes that characterize the expression profile of solid tumor TEMs,
belonging to those required for tumor angiogenesis [27]. In fact, IL1β is a major cytokine link-
ing inflammation and angiogenesis in tumor neoangiogenesis [28] and it has been reported to
cause the rapid expression of TYMP, an important enzyme involved in the nucleoside metabo-
lism, that is induced by inflammation or micro-environmental stress, in particular as a conse-
quence of chemotherapeutic treatment [29, 30]. Its over expression protects cells from
apoptosis, promotes angiogenesis and it has been found in a wide range of human cancer tis-
sues [31]. Similarly, HPSE, CTNNB1 and TIMP-1 over expression has been described to be
implicated in both pathological and physiological processes focusing on angiogenesis [32–34]
as well as a significant high expression of CXCR4 has been reported to characterize monocytes
with presumed reparative/angiogenic properties [35]. The transcription factor SPI1 (PU.1),
whose link with the V617F Jak2 mutation has been described [36], has also been associated, in
a chick yolk-sac experimental model system, with an angiogenic activity of macrophages that is
mediated by the RXR family of nuclear receptors [37]. Thus, our molecular investigations
bring support to a possible role played by Tie2+ monocytes in favouring neoangiogenesis in the
spleen of patients with PMF.
In conclusion our data suggest that angiogenic monocytes accumulate in the spleen of
patients with PMF in close proximity of vessels, and that this phenomenon likely modulates
the peripheral trafficking of these cells. They also show that spleen derived angiogenic mono-
cytes from patients with PMF express genes involved in angiogenesis that may contribute to
the formation of an abnormal capillary network.
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